NCT01365351

Brief Summary

The purpose of this study is to investigate long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,034

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2007

Longer than P75 for all trials

Geographic Reach
1 country

59 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2007

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

June 1, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 3, 2011

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

June 2, 2017

Status Verified

June 1, 2017

Enrollment Period

8.5 years

First QC Date

June 1, 2011

Last Update Submit

June 1, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy of ZOMACTON

    measured by: body height, increase of body height per annum

    Up to 5 years

Secondary Outcomes (2)

  • Efficacy measured by further parameters

    Up to 5 years

  • Safety of Zomacton and application device

    Up to 5 years

Study Arms (1)

Growth hormone

Children with growth hormone deficiency

Other: Growth hormone

Interventions

Drug given by prescription

Growth hormone

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Clinics and private practices

You may qualify if:

  • therapeutic need according to SPC
  • written informed consent

You may not qualify if:

  • contraindications according to SPC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (59)

Investigational Site

Konrad-Adenauer-Allee 33, Augsburg, Germany

Location

Investigational Site

Friedrichstr. 36-42, Dresden, Germany

Location

Investigational Site

Blücherstr. 4, Erfurt, Germany

Location

Investigational Site

Loschgestr. 15, Erlangen, Germany

Location

Investigational Site

Düsseldorfer Str. 1-7, Frankfurt (Main), Germany

Location

Investigational Site

Stresemannallee 1-3, Frankfurt (Main), Germany

Location

Investigational Site

Wilhelm-Breckow-Allee 20, Gummersbach, Germany

Location

Investigational Site

Seminarstr. 2, Heidelberg, Germany

Location

Investigational Site

Koblenzer Str. 115-155, Koblenz, Germany

Location

Investigational Site

Elisenstr. 12, Oldenburg, Germany

Location

Investigational Site

Elisabethenstr. 15, Ravensburg, Germany

Location

Investigational Site

Chausseestr. 119, State of Berlin, Germany

Location

Investigational Site

Marienstr. 6-8, Vechta, Germany

Location

Investigational Site, Geranienweg 7

Bad Langensalza, Germany

Location

Investigational Site, Augustenburger Platz 1

Berlin, Germany

Location

Investigational Site, Chausseestraße 119

Berlin, Germany

Location

Investigational Site. Gotlindestraße 2 - 20

Berlin, Germany

Location

Investigational Site, Burgsteig 13

Bielefeld, Germany

Location

Investigational Site, Alexandrinenstraße 5

Bochum, Germany

Location

Investigational Site, Alter Markt 4

Bochum, Germany

Location

Investigational Site, Flemmingstraße 4

Chemnitz, Germany

Location

Investigational Site, Kerpener Str. 62 (Haus 26)

Cologne, Germany

Location

Investigational Site, Dr.-Friedrich-Steiner-Straße 5

Datteln, Germany

Location

Investigational Site, Fetscherstraße 74

Dresden, Germany

Location

Investigational Site, Hospitalstraße 44

Düren, Germany

Location

Investigational Site, Düsseldorfer Straße 8

Düsseldorf, Germany

Location

Investigational Site, Hufelandstraße 55

Essen, Germany

Location

Investigational Site, Lyoner Straße 54

Frankfurt am Main, Germany

Location

Investigational Site, Mathildenstraße 1

Freiburg im Breisgau, Germany

Location

Investigational Site, Pippinplatz 4

Gauting, Germany

Location

Investigational Site, Am Markt 3

Gehrden, Germany

Location

Investigational Site, Robert-Koch-Straße 40

Göttingen, Germany

Location

Investigational Site, Ernst-Grube-Straße 40

Halle, Germany

Location

Investigational Site, Bleickenallee 38-40

Hamburg, Germany

Location

Investigational Site, Lornsenstraße 4-6

Hamburg, Germany

Location

Investigational Site, Werlerstraße 130

Hamm, Germany

Location

Investigational Site, Brabeckstraße 153

Hanover, Germany

Location

Investigational Site, Im Neuenheimer Feld 430

Heidelberg, Germany

Location

Investigational Site, Seminarstraße 2

Heidelberg, Germany

Location

Investigational Site, Kirrberger Straße

Homburg, Germany

Location

Investigational Site, Kochstraße 2

Jena, Germany

Location

Investigational Site, Ettlinger Straße 27

Karlsruhe, Germany

Location

Investigational Site, Schwanenweg 20

Kiel, Germany

Location

Investigational Site, Koblenzer Str. 115-155

Koblenz, Germany

Location

Investigational Site, Lutherplatz 40

Krefeld, Germany

Location

Investigational Site, Johannisplatz 1

Leipzig, Germany

Location

Investigational Site, Liebigstraße 20 a

Leipzig, Germany

Location

Investigational Site, Birkenallee 34

Magdeburg, Germany

Location

Investigational Site, Leipziger Straße 44

Magdeburg, Germany

Location

Investigational Site, Kölner Platz 1

München, Germany

Location

Investigational Site, Lindwurmstraße 4

München, Germany

Location

Investigational Site, Promenadeplatz 12

München, Germany

Location

Investigational Site, Albert-Schweitzer-Straße 33

Münster, Germany

Location

Investigational Site, Helmut-Just-Straße 6

Neubrandenburg, Germany

Location

Investigational Site, St.-Johannis-Mühlgasse 19

Nuremberg, Germany

Location

Investigational Site, Dr.-Eden-Straße 10

Oldenburg, Germany

Location

Investigational Site, Hauptkanal rechts 75

Papenburg, Germany

Location

Investigational Site, Pettenkoferstraße 10

Rosenheim, Germany

Location

Investigational Site, Eythstraße 24

Ulm, Germany

Location

MeSH Terms

Conditions

Dwarfism, Pituitary

Interventions

Growth Hormone

Condition Hierarchy (Ancestors)

DwarfismBone Diseases, DevelopmentalBone DiseasesMusculoskeletal DiseasesBone Diseases, EndocrineHypopituitarismPituitary DiseasesHypothalamic DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, AnteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Clinical Development Support

    Ferring Pharmaceuticals

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2011

First Posted

June 3, 2011

Study Start

December 1, 2007

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

June 2, 2017

Record last verified: 2017-06

Locations